GSK wins $235 million from Teva in Coreg patent trial
June 21, 2017 at 18:41 PM EDT
June 21 (Reuters) - A U.S. jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg, court documents showed.
